Nichi-Iko and Laboratorio Elea Phoenix announce deal for biosimilar infliximab

Jun 17, 2021

Nichi-Iko announced it has entered a licence and supply agreement with Laboratorio Elea Phoenix for a biosimilar infliximab product. Under the agreement Nichi-Iko will supply the product to Elea for the Argentine market.

Print Page Mail Article